← All Mesothelioma Diagnosis Flashcard Decks

Biomarkers and Lab Tests Flashcards

6 cards from real Mesothelioma Diagnosis practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 6 Biomarkers and Lab Tests flashcards as text
  1. Which laboratory finding in pleural fluid analysis is characteristic of a malignant exudative effusion?

    Answer: High LDH and high protein

    Malignant pleural effusions are exudates characterized by high LDH (>200 IU/L) and high protein (>3 g/dL) using Light's criteria.

  2. Which complete blood count (CBC) finding is associated with advanced mesothelioma and poor prognosis?

    Answer: Thrombocytosis

    Paraneoplastic thrombocytosis (elevated platelet count) is common in advanced mesothelioma and is associated with poor survival outcomes.

  3. What does an elevated serum CRP (C-reactive protein) indicate in the context of mesothelioma?

    Answer: Active systemic inflammation associated with worse prognosis

    Elevated CRP reflects tumor-driven systemic inflammation in mesothelioma and is an independent predictor of poor prognosis.

  4. Hyaluronan (hyaluronic acid) levels are elevated in pleural fluid of mesothelioma patients. This is because:

    Answer: Mesothelioma cells produce large amounts of hyaluronan

    Malignant mesothelial cells actively secrete hyaluronan into pleural fluid, and markedly elevated levels support a mesothelioma diagnosis.

  5. Which germline mutation significantly increases the lifetime risk of developing mesothelioma?

    Answer: BAP1 mutation

    Germline BAP1 mutations define the BAP1 tumor predisposition syndrome, which markedly increases the risk of mesothelioma, uveal melanoma, and other cancers.

  6. What is the role of next-generation sequencing (NGS) in mesothelioma diagnosis?

    Answer: Identifying actionable mutations and confirming malignancy

    NGS identifies somatic mutations (e.g., BAP1, NF2, CDKN2A) that confirm malignancy and may reveal targetable alterations for clinical trials.